An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Inclusion Criteria:
Exclusion Criteria:
Boynton Beach, California 33426, United States
Coevr d'Alene, Idaho 83814, United States
Indiannapolis, Indiana 46202, United States